To investigate the efficacy and safety of LOP（asparaginase + vincristine + dexamethasone） chemotherapy combined with radiotherapy in patients with nasal NK/T cell lymphoma. Sixty patients with nasal NK/T cell lymphoma admitted to our hospital from February 2012 to February 2016 were selected as the study subject. They were randomly divided into group A and group B, 30 cases in each group. All patients were treated with combined chemotherapy and IMRT（intensity modulated conformal radiotherapy）. The LOP regimen was used in group A and the CHOP（cyclophosphamide + pirarubicin + vincristine + dexamethasone） regimen was used in group B. The short-term efficacy, long-term efficacy and adverse reactions of the two groups were compared. The clinical manifestations of 60 patients mainly included nasal obstruction（81.67%）, accompanied by fever, headache, nosebleed and runny nose. Forty-one patients（68.33%） had only one site of lesion, and 21 patients（35.00%） had multiple sites of lesions. In terms of total remission rate, it was significantly higher in group A than that in group B（93.33% vs. 66.67%, <0.05）. In terms of adverse reactions, the incidence of bone marrow suppression, gastrointestinal reaction and low-protein reaction was significantly lower in group A than that in group B（<0.05）. Three patients died in group A and 11 patients died in group B during the 3-year follow-up. The 3-year survival rate of group A was higher than that of group B（<0.05）. Compared with CHOP+IMRT regimen, the LOP+IMRT regimen for nasal NK/T-cell lymphoma patients resulted in higher overall remission rate, survival rate and lower adverse reactions, so it is worth in clinical promotion.